Roquefort Therapeutics (LON:COIL) Releases Earnings Results

Roquefort Therapeutics (LON:COIL) announced its earnings results on Monday. The company reported GBX (1.66) EPS for the quarter, Digital Look Earnings reports. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 18.71%.

Roquefort Therapeutics Stock Up 1.8%

Shares of Roquefort Therapeutics stock opened at GBX 7.25 on Monday. Roquefort Therapeutics has a 1-year low of GBX 6.75 and a 1-year high of GBX 12.50. The company has a market capitalization of £30.94 million, a PE ratio of -0.33 and a beta of 0.05. The company has a debt-to-equity ratio of 8.18, a current ratio of 0.63 and a quick ratio of 3.07. The business has a 50-day moving average of GBX 8.97 and a 200-day moving average of GBX 9.33.

Analyst Ratings Changes

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Roquefort Therapeutics in a research report on Monday, September 21st.

About Roquefort Therapeutics

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.